Literature DB >> 21631475

Sex-related differences in animal models of migraine headache.

Hayrunnisa Bolay1, Nancy E J Berman, Didem Akcali.   

Abstract

Trigeminal nerve-mediated pain disorders such as migraine, temporomandibular joint disorder, and classical trigeminal neuralgia are more prevalent in women than in men. Female laboratory animals also show greater responses to various nociceptive stimuli than male animals. However, current knowledge of migraine pathogenesis is based primarily on experimental studies conducted in male animals and lack of migraine research with female animals limits clinical relevance. Migraine is triggered by any alteration in the intrinsic or extrinsic milieu and women at reproductive age are continuously prone to waxing and waning effects of female sex hormones. The experimental approach to this problem is complex because the rodent estrous cycle differs from the human cycle, and because exogenous hormone replacement in ovariectomized females has its limitations. The existence of multiple estrogen receptors in the trigeminal system also presents a challenge. Estrogens do not seem to directly affect calcitonin gene-related peptide or 5-HT(1D) receptors in the trigeminal system. Nonetheless, 2 estrogen receptors activate MAPK/ERK signaling pathway that mediates nociceptive processing in trigeminal nucleus caudalis. In addition, estrogen enhances susceptibility to cortical spreading depression, the neurobiological event underlying migraine aura, which may be independent of the estrous cycle. Further studies in female animals are required to clarify mechanisms underlying sex differences with respect to fluctuating sex hormones, cortical spreading depression, and excitability of the trigeminovascular system.
© 2011 American Headache Society.

Entities:  

Mesh:

Year:  2011        PMID: 21631475     DOI: 10.1111/j.1526-4610.2011.01903.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  18 in total

Review 1.  Transdermal hormonal therapy in perimenstrual migraine: why, when and how?

Authors:  Cristina Tassorelli; Rosaria Greco; Marta Allena; Erica Terreno; Rossella E Nappi
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 2.  Migraine and estrogen.

Authors:  Nu Cindy Chai; B Lee Peterlin; Anne H Calhoun
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

Review 3.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 4.  Sex-related differences in migraine.

Authors:  Cinzia Finocchi; Laura Strada
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

5.  Her versus his migraine: multiple sex differences in brain function and structure.

Authors:  Nasim Maleki; Clas Linnman; Jennifer Brawn; Rami Burstein; Lino Becerra; David Borsook
Journal:  Brain       Date:  2012-08       Impact factor: 13.501

Review 6.  Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.

Authors:  Catherine A Christian; Doodipala Samba Reddy; Jamie Maguire; Patrick A Forcelli
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

7.  Mechanisms of G protein-coupled estrogen receptor-mediated spinal nociception.

Authors:  Elena Deliu; G Cristina Brailoiu; Jeffrey B Arterburn; Tudor I Oprea; Khalid Benamar; Nae J Dun; Eugen Brailoiu
Journal:  J Pain       Date:  2012-08       Impact factor: 5.820

8.  Potential role of aromatase over estrogen receptor gene polymorphisms in migraine susceptibility: a case control study from North India.

Authors:  Jayashri Ghosh; Gunjan Joshi; Sunil Pradhan; Balraj Mittal
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

9.  Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days.

Authors:  Gabriele S Merki-Feld; Bruno Imthurn; Ronald Langner; Burkhardt Seifert; Andreas R Gantenbein
Journal:  J Headache Pain       Date:  2015-05-01       Impact factor: 7.277

Review 10.  Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?

Authors:  Rossella E Nappi; Gabriele S Merki-Feld; Erica Terreno; Alice Pellegrinelli; Michele Viana
Journal:  J Headache Pain       Date:  2013-08-01       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.